Ipamorelin 5mg

THIS PRODUCT IS INTEDED AS A RESEARCH CHEMICAL ONLY.
This designation allows the use of research chemicals strictly in vitro for testing and laboratory experimentation only. All products information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professional. This product is not a drug, food or cosmetic and may not be misbranded, misused or mislabled as a drug food or cosmetic.

What is Ipamorelin 5 mg?

Ipamorelin 5 mg is a small, man-made pentapeptide. It works by switching on the ghrelin receptor (GHS-R1a), and by doing so it makes the body release its own growth hormone. It does this with little effect on cortisol or prolactin — a narrower action than many older growth-hormone secretagogues. Because of that narrower action, researchers study it for muscle repair, recovery, metabolism and the body's response to stress.

Do not mistake interest for proof. Ipamorelin is not approved by the FDA and is supplied only as a freeze-dried powder for laboratory research. It is not a medicine, a supplement, or a therapy. The evidence for anything beyond basic biological effect comes mainly from cell work, animal tests and a few small human studies — not from large, conclusive trials.

Chemical Makeup: Molecular Identity & Class  

Peptide class: Synthetic pentapeptide; selective GHS-R1a agonist  
Amino Acid Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂  
Molecular Formula: C₃₈H₄₉N₉O₅  
Molecular Weight: 711.86–711.87 g/mol
Synonyms: NNC 26-0161, Ipamorelin acetate  
Physical Properties: White lyophilized powder, soluble in water/DMSO/acids  
CAS Number: 170851-70-4 

Ipamorelin is built with D-amino acids not found in nature. They give the molecule stability and focus, making it a strong and selective trigger for growth hormone release. Simple in design, deliberate in purpose.

It is stable at –20 °C and distributed for research in sealed vials.

Structure: Sequence & Notation  

Ipamorelin is a small peptide built from five amino-acid residues: Aib, His, D-2-Nal, D-Phe and Lys-NH₂. It combines both standard and altered (non-natural) residues so as to act selectively at the ghrelin receptor. The sequence is held together by simple amide bonds; there are no sugar groups attached. Plain and spare: designed for a single, specific purpose.

SMILES: CC(C)(C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N)N

Research Overview: Effects, Mechanisms, and Gaps

Effects on Corticosteroids & Stress Response  

Ipamorelin demonstrates selective activation of the GH axis without marked changes in ACTH or cortisol, even at doses exceeding the ED₅₀ for GH stimulation. Compared to older GHS peptides (GHRP-2, GHRP-6), animal and human studies report negligible stimulation of pituitary stress hormones and no significant stress response elevation. This selectivity is advantageous in clinical research aimed at promoting muscle/bone health during corticosteroid therapy, with some rat studies confirming mitigation of glucocorticoid-induced muscle weakness and bone loss. However, published human studies are few, and the evidence for mitigating stress hormone effects is largely limited to animal models.

(cite:  Animal study comparison;  Rat study;  In vitro selectivity report)

Ipamorelin & Bone Health  

In animal experiments ipamorelin shows signs of helping bone. It spurs osteoblasts to make bone and checks the cells that break it down, so total mineral content goes up. In old rats, DEXA scans and microstructural studies find more periosteal bone and a firmer internal architecture. Human evidence is scant: a few small trials note changes in bone-turnover markers, but nothing like proof. Promising signals — not certainty. No FDA-registered indications exist for osteoporosis or fracture prevention; the data is promising yet preliminary.

(cite:  Animal & rat studies;  Experimental review)

Muscle Growth & Body Composition  

Research points to a clear pattern: ipamorelin tends to build muscle and lessen fat. It works mainly through the body's own growth hormone system. In trials with middle-aged men and in old rats, subjects gained lean mass and showed higher rates of protein synthesis. Shifts in insulin response and blood lipids were mild and secondary. The effect seems steady, limited, and measurable — not dramatic, but real enough to draw scientific notice.

 Most controlled trials are short-term and limited in size. Human studies also suggest improvement in grip strength and body composition in sarcopenic elders, yet all reports note the need for larger, longer-duration trials to confirm these findings.

(cite:  Human/animal studies;  UCLA study (male subjects);  Clinical nutrition/ISSMN study)

Other Reported Effects & Biological Mechanisms  

Ipamorelin has shown effects on glucose metabolism, insulin release, sleep regulation, tissue repair, and (in limited studies) neuroprotection. Animal research suggests ipamorelin stimulates pancreatic insulin secretion, especially under certain stress conditions. Small human trials report improved sleep patterns and enhanced tissue recovery post-injury, with anecdotal cases mentioning better skin and hair characteristics. Most research remains preliminary, non-randomized, or in vitro.

(cite:  Sleep/metabolism trial;  Pancreatic secretion study)

Research Gaps & Neglected Areas  

For all its promise in animals, much about ipamorelin remains unknown. We do not yet know if it is safe over the long term in humans. No solid trials prove it can treat lasting metabolic or muscular problems. Its influence on stress, hormones, and the wider neuroendocrine system is barely studied. What we have is early evidence — interesting, but incomplete.

The FDA, EMA, and peer research bodies caution against extrapolating animal study data to clinical benefit in human populations. Existing data may be confounded by peptide impurities, batch variance, and publication bias.

(cite:  Review of future research pathways;  FDA impurity note)

Safety & Side Effects  

Ipamorelin, in the short term, behaves like most small experimental drugs: it usually does no great harm and, when it does, the harm is small and soon passes. Most complaints are ordinary and fleeting — redness or soreness where the needle went in, a headache, a touch of nausea or dizziness, tiredness, an appetite that wakes up, a little water weight, joint aches, an odd tingle or numbness. People with diabetes must take heed: blood sugar can wobble. Rarely, graver things happen — allergic reactions, abrupt changes of mood, sudden swelling — and when they do they demand a doctor's attention. Deeper risks — cancer, immune shifts, heart trouble — are at present guesses; we have not yet the evidence to call them fact. Do not use Ipamorelin in pregnancy, in the presence of an active cancer, with uncontrolled diabetes, or in severe heart disease. Any study — of animals or of humans — should be watched by clinical monitors.

This is not medical advice. The product is sold for research only. Anyone thinking of using Ipamorelin experimentally or therapeutically should see a qualified clinician and obey the law.